ZBH|Analyst Targets
ZBH|Company Info
ZBH|Insider Trading
ZBH|Fundamentals
ZBH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.88 | - | - |
| Q2'26 | $2.03 | $2.07 | +2.0% |
| Q4'25 | $1.91 | $2.42 | +26.8% |
| Q3'25 | $1.87 | $1.90 | +1.8% |
| Q2'25 | $1.98 | $2.07 | +4.8% |
| Q1'25 | $1.77 | $1.81 | +2.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.1B | - | - |
| Q2'26 | $2.2B | $2.2B | +1.0% |
| Q4'25 | $2.1B | $2.2B | +9.0% |
| Q3'25 | - | $2.0B | - |
| Q2'25 | - | $2.1B | - |
| Q1'25 | - | $1.9B | - |
ZBH|Monthly Returns
Market Data
ZBH Stock Snapshot
- Market cap
- 17.84B
- P/E ratio
- 22.1
- Day range
- $90.65 – $92.61
- News sentiment
- 71/100 · Bullish
- Analyst target
- $106.82 (+17.0%)
- Consensus
- Hold · 35 analysts
The signals on ZBH lean bearish, and the range position backs that up. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Reverse DCF
What growth is priced into ZBH?
At today's price, Zimmer Biomet Holdings, Inc. needs to grow free cash flow about -3.7% a year for the next 10 years to justify its valuation at a 7.10% cost of capital. Over its actual history it has compounded free cash flow at 2.7% a year, so the market is asking for 6.4 percentage points below its own delivered rate. On that basis ZBH looks priced below what its own growth record supports.
- Implied FCF growth
- -3.7%
- Historical FCF CAGR
- 2.7%
- Growth gap
- -6.4 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 7.10%
- Beta
- 0.49
Behaviour On Record
What ZBH's own history says about today's numbers
- Realized volatility (21d)
- 30.2% 80th pct
- Below its peak
- -46.9%
- vs 200-day average
- +0.8%
- Up days (1y)
- 53%
Zimmer Biomet Holdings, Inc. is currently running 30.2% annualised volatility over the last 21 sessions. Measured against ZBH's own 13 years of daily returns rather than a market-wide average, that is the 80th percentile — elevated for this stock, against a typical reading of 22.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
ZBH is trading -46.9% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -24.1%, and the deepest was -49.7% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +0.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 55th percentile — close to the gap it normally carries. Over the past year ZBH closed higher on 53% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 14 years of records, ZBH finished the month higher 8 of 14 times, with a median return of +1.5% and an average of -0.4%. Its strongest month historically has been July at +4.0% on average, its weakest September at -2.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: ZBH has opened more than 2% away from the prior close in 110 of 3,268 sessions (3.4% of the time), with the largest gaps running +8.7% and -9.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against ZBH's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ZBH's sector?
Zimmer Biomet Holdings, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, ZBH ranks 3rd of 15 tracked industries, leading.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
- Industry rank
- #3 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on ZBH?
Barclays most recently initiated coverage on Zimmer Biomet Holdings, Inc. to Equal-Weight on Oct 7, 2026 with a price target of $100. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Barclays — Equal-Weight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
ZBH peers & ETF holders
Medical DevicesMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 23,483,741 | 12.12% | $2.11B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 15,614,847 | 8.06% | $1.34B | 2026-08-07 |
| Harris Associates L P | ▼ Sell | 12,738,025 | 6.57% | $1.10B | 2026-08-14 |
| Geode Capital Management, LLC | ▼ Sell | 5,349,223 | 2.76% | $458.75M | 2026-08-12 |
| Invesco Ltd. | ▲ Buy | 3,979,860 | 2.05% | $342.63M | 2026-08-14 |
| Citadel Advisors LLC | ▲ Buy | 3,477,472 | 1.79% | $299.38M | 2026-09-02 |
| Morgan Stanley | ▲ Buy | 2,591,503 | 1.34% | $223.10M | 2026-08-13 |
| Bank of America Corp | ▲ Buy | 2,177,724 | 1.12% | $187.48M | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 1,965,052 | 1.01% | $169.17M | 2026-08-13 |
| Norges Bank | ▼ Sell | 1,587,431 | 0.82% | $136.66M | 2026-08-12 |
| Goldman Sachs Group Inc | ▼ Sell | 968,628 | 0.50% | $83.39M | 2026-08-14 |
| Point72 Asset Management, L.P. | ▲ Buy | 879,851 | 0.45% | $75.75M | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 815,914 | 0.42% | $74.44M | 2026-08-12 |
| AQR Capital Management LLC | ▲ Buy | 367,365 | 0.19% | $31.29M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 258,982 | 0.13% | $22.30M | 2026-08-03 |
| AllianceBernstein L.P. | ▼ Sell | 214,937 | 0.11% | $19.43M | 2026-08-14 |
| Millennium Management LLC | ▼ Sell | 222,065 | 0.11% | $19.12M | 2026-08-14 |
| Moore Capital Management, LP | ▲ Buy | 198,642 | 0.10% | $17.10M | 2026-08-14 |
| ExodusPoint Capital Management, LP | ▲ Buy | 180,884 | 0.09% | $15.57M | 2026-08-14 |
| Wells Fargo & Company | ▼ Sell | 178,591 | 0.09% | $15.37M | 2026-08-14 |
| Schonfeld Strategic Advisors LLC | ▲ Buy | 603,216 | 0.31% | $12.73M | 2026-08-14 |
| Marshall Wace, LLP | ▲ Buy | 144,500 | 0.07% | $12.44M | 2026-08-13 |
| Neuberger Berman Group LLC | ▼ Sell | 129,573 | 0.07% | $11.15M | 2026-08-13 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 96,942 | 0.05% | $8.35M | 2026-08-14 |
| Prudential Financial Inc | ▼ Sell | 91,756 | 0.05% | $7.90M | 2026-08-12 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-05-15 | 2025-05-31 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-04-08 | 2025-05-08 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-02-11 | 2025-03-12 |
| John F. Reed | Senate | RI | ▼ Sell | $1K - $15K | 2016-12-16 | 2017-01-04 |
| John F. Reed | Senate | RI | ▼ Sell | $1K - $15K | 2016-07-25 | 2016-07-27 |